How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

Adelle Dawson; Bushra S Rana; Stuart D Pringle; Louise A Donnelly; Andrew D Morris; Allan D Struthers

doi:10.1097/01.hjh.0000125408.50839.b8

How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

Adelle Dawson, Bushra S Rana, Stuart D Pringle, Louise A Donnelly, Andrew D Morris, Allan D Struthers

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.

Original language	English
Pages (from-to)	1403-8
Number of pages	6
Journal	Journal of Hypertension
Volume	22
Issue number	7
DOIs	https://doi.org/10.1097/01.hjh.0000125408.50839.b8
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.hjh.0000125408.50839.b8

Fingerprint

Dive into the research topics of 'How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?'. Together they form a unique fingerprint.

Cite this

Dawson, A., Rana, B. S., Pringle, S. D., Donnelly, L. A., Morris, A. D., & Struthers, A. D. (2004). How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? Journal of Hypertension, 22(7), 1403-8. https://doi.org/10.1097/01.hjh.0000125408.50839.b8

@article{73cbaa52e2524cafbd7a43b5e5c8b2b0,

title = "How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?",

abstract = "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.",

author = "Adelle Dawson and Rana, {Bushra S} and Pringle, {Stuart D} and Donnelly, {Louise A} and Morris, {Andrew D} and Struthers, {Allan D}",

year = "2004",

doi = "10.1097/01.hjh.0000125408.50839.b8",

language = "English",

volume = "22",

pages = "1403--8",

journal = "Journal of Hypertension",

issn = "0263-6352",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

Dawson, A, Rana, BS, Pringle, SD, Donnelly, LA, Morris, AD & Struthers, AD 2004, 'How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?', Journal of Hypertension, vol. 22, no. 7, pp. 1403-8. https://doi.org/10.1097/01.hjh.0000125408.50839.b8

How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? / Dawson, Adelle; Rana, Bushra S; Pringle, Stuart D et al.
In: Journal of Hypertension, Vol. 22, No. 7, 2004, p. 1403-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

AU - Dawson, Adelle

AU - Rana, Bushra S

AU - Pringle, Stuart D

AU - Donnelly, Louise A

AU - Morris, Andrew D

AU - Struthers, Allan D

PY - 2004

Y1 - 2004

N2 - The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.

AB - The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.

U2 - 10.1097/01.hjh.0000125408.50839.b8

DO - 10.1097/01.hjh.0000125408.50839.b8

M3 - Article

C2 - 15201558

SN - 0263-6352

VL - 22

SP - 1403

EP - 1408

JO - Journal of Hypertension

JF - Journal of Hypertension

IS - 7

ER -